世界の白血球アフェレーシス療法市場(~2026年):製品別(デバイス、フィルター、カラム、使い​​捨て品)、ロイコパック別(可動性、非可動性)、疾患別(ALL、NHL、多発性骨髄腫)、用途別(研究、治療)、エンドユーザー別(病院、製薬、バイオテクノロジー)

◆英語タイトル:Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026
◆商品コード:MD6538
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2029年4月15日
◆ページ数:240
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は、世界の白血球アフェレーシス療法市場規模が2021年61百万ドルから2026年91百万ドルまで、年平均8.4%成長すると予測しています。本調査レポートでは、白血球アフェレーシス療法の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業動向、種類別(使い​​捨て品、デバイス)分析、用途別(研究、治療)分析、エンドユーザー別(血液成分提供者&血液センター、学術&研究機関、製薬&バイオテクノロジー企業、病院&輸血センター)分析、ロイコパック別(可動性、非可動性)分析、地域別分析、競争状況、企業情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・産業動向
・世界の白血球アフェレーシス療法市場規模:種類別(使い​​捨て品、デバイス)
・世界の白血球アフェレーシス療法市場規模:用途別(研究、治療)
・世界の白血球アフェレーシス療法市場規模:エンドユーザー別(血液成分提供者&血液センター、学術&研究機関、製薬&バイオテクノロジー企業、病院&輸血センター)
・世界の白血球アフェレーシス療法市場規模:ロイコパック別(可動性、非可動性)
・世界の白血球アフェレーシス療法市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global leukaphereis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period.”
The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis andc cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.

“The leukapheresis disposables segment holds the highest market share, by product, in the leukapheresis products market,
in the forecast period.”
On the basis of product, the leukapheresis market is broadly segmented into leukapheresis disposables and leukaphersis devices. Leukapheresis devices are further segmented into centrifugal devices and membrane separators. The large share of the leukapheresis disposables segment can be attributed to the recurrent use of disposables during leukapheresis procedures, increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.

“The centrifugal devices segment to grow at the highest CAGR in the leukapheresis devices market, in the forecast period.”
Based on type, the leukapheresis devices market is broadly segmented into centrifugal devices and membrane separators. Centrifugal devices segment is expected to grow at the higest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis.

“Increasing adoption of leukapheresis products for development of cell-based immunotherapies to promote the growth of this segment in the forecast period.”
Based on application, the leukapheresis products market is segmented into research and therapeutic applications. The research applications segment accounted for the largest share of the leukapheresis products market during the forecast period. The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies and leukapheresis-derived primary cells in drug development.

“In the leukapheresis products market by end user segment, blood component providers & blood centers segment holds the highest market share”
On the basis of end user, the leukapheresis products market is segmented into blood component providers & blood centers, academic and research institutes, pharmaceutical & biotechnology companies, hospitals & transfusion centers. Blood component providers & blood centers hold the largest share in this market. The large share of this segment can be attributed to growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.

“In the leukopaks market by type, the diseased leukopaks segment is projected to grow at the highest rate in forecast period”
Based on type, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.

“Acute Lymphocytic Leukemia holds the largest share in the leukopaks market, by indication, in the forecast period”
Based on indication, the leukopaks market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer, and other indications (colorectal cancer, neuroblastoma, breast cancer, and acute myeloid leukemia). The acute lymphocytic leukemia segment accounts for the largest share of the leukopaks market, by indication. The large share of this segment can be attributed to the increasing focus of pharmaceutical companies on the development of leukopak-based cell therapies for the treatment of acute lymphocytic leukemia (ALL) and a high number of CAR T-cell therapy clinical trials for ALL.

“Acute Lymphocytic Leukemia holds the largest share in the leukopaks market, by indication, in the forecast period”
Based on indication, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.

“The pharmaceutical and biotechnology companies segment to grow at the highest CAGR in the leukopaks market, by end user, in the forecast period”
By end user, the leukopaks market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Pharmacuetical and biotechnology companies are projected to grow at the highest CAGR in this market in the forecast period. Thi highest growth rate can be attributed to increasing collaboration of pharmaceutical companies with academic institutes, research centers, and hospitals for new drug development.

“North America holds the largest share in the leukaphereis and leukopaks market, by region, in the forecast period”
The leukapheresis and leukopaks market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The large share of this region can be attributed to the increasing adoption of leukapheresis products for the development of leukoreduced plasma and leukoreduced RBCs, growing adoption of leukopaks as a source of primary cells for research applications, increasing number of clinical trials for the development of CAR T-cell therapy using leukopaks.

A breakdown of the primary participants for the leukapheresis market referred to for this report is provided below:
• By Company Type: Tier 1–30%, Tier 2–25%, and Tier 3–45%
• By Designation: C-level–40%, Director Level–35%, and Others–25%
• By Region: North America–36%, Europe–26%, Asia Pacific–21%, Rest of the World – 17%

A breakdown of the primary participants for the leukopaks market referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–38%, and Tier 3–22%
• By Designation: C-level–40%, Director Level–35%, and Others–25%
• By Region: North America–39%, Europe–28%, Asia Pacific–22%, Rest of the World – 11%

The prominent players in the global leukapheresis and leukopaks market are Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy), PuriBlood Medical Co. Ltd. (Taiwan), and Beijing ZKSK Technology Co. Ltd. (China). Some prominent players in the leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).

Research Coverage:
The report analyzes the market for various leukapheresis and leukopaks product and their adoption pattern. It aims at estimating the market size and future growth potential of the global leukapheresis and leukopaks market and different segments such as product, application, indication, end user and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global leukapheresis products and leukopaks market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global leukapheresis products and leukopaks market
• Market Development: Comprehensive information on the lucrative emerging regions by products, end user, and region
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global leukapheresis products and leukopaks market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the global leukapheresis products and leukopaks market.

【レポートの目次】

1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.3.2 YEARS CONSIDERED FOR THE STUDY 33
1.4 CURRENCY 33
TABLE 1 STANDARD CURRENCY CONVERSION RATES 33
1.5 LIMITATIONS 33
1.6 STAKEHOLDERS 34
1.7 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 1 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Key data from secondary sources 38
2.1.2 PRIMARY DATA 39
FIGURE 2 PRIMARY SOURCES 39
2.1.2.1 Key data from primary sources 40
2.1.2.2 Insights from primary experts 41
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS & LEUKOPAKS MARKET) 41
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION (LEUKAPHERESIS MARKET) 42
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET) 42
2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET 43
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 43
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION 44
FIGURE 8 REVENUE ANALYSIS OF THE TOP 4 COMPANIES: LEUKAPHERESIS MARKET (2020) 45
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS MARKET) 46
FIGURE 10 TOP-DOWN APPROACH 47
2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET 48
FIGURE 11 VOLUME ESTIMATION OF LEUKOPAKS MARKET 49
FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKOPAKS MARKET) 50
FIGURE 13 TOP-DOWN APPROACH 50
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 51
FIGURE 14 MARKET DATA TRIANGULATION METHODOLOGY 51
2.5 MARKET SHARE ANALYSIS 52
2.6 ASSUMPTIONS FOR THE STUDY 52
2.7 RISK ASSESSMENT 52
TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS & LEUKOPAKS MARKET 52
2.8 COVID-19 HEALTH ASSESSMENT 53
2.9 COVID-19 ECONOMIC ASSESSMENT 53
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 54
FIGURE 15 CRITERIA IMPACTING THE GLOBAL ECONOMY 54
FIGURE 16 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 55
2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN
THE LEUKAPHERESIS AND LEUKOPAKS MARKET 56
3 EXECUTIVE SUMMARY 57
FIGURE 17 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 57
FIGURE 18 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 58
FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 58
FIGURE 20 LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 59
FIGURE 21 LEUKOPAKS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 59
FIGURE 22 LEUKOPAKS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION) 60
FIGURE 23 LEUKOPAKS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 60
FIGURE 24 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET 61
FIGURE 25 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET 62
4 PREMIUM INSIGHTS 63
4.1 LEUKAPHERESIS PRODUCTS MARKET OVERVIEW 63
FIGURE 26 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET GROWTH 63
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY 63
FIGURE 27 LEUKAPHERESIS DISPOSABLES COMMANDED THE LARGEST SHARE OF
THE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2020 63
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX 64
FIGURE 28 CHINA TO WITNESS THE HIGHEST GROWTH IN THE LEUKAPHERESIS PRODUCTS MARKET DURING THE FORECAST PERIOD 64
4.4 REGIONAL MIX: LEUKAPHERESIS PRODUCTS MARKET 64
FIGURE 29 NORTH AMERICA DOMINATED THE MARKET IN 2020 64
4.5 LEUKOPAKS MARKET OVERVIEW 65
FIGURE 30 FAVORABLE GOVERNMENT SUPPORT AND RISING DEMAND FOR LEUKOPAKS IN RESEARCH APPLICATIONS TO DRIVE MARKET GROWTH 65
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY 66
FIGURE 31 MOBILIZED LEUKOPAKS COMMANDED THE LARGEST SHARE OF
THE NORTH AMERICAN LEUKOPAKS MARKET IN 2020 66
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX 67
FIGURE 32 CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 67
4.8 REGIONAL MIX: LEUKOPAKS MARKET 67
FIGURE 33 APAC MARKET TO WITNESS THE HIGHEST GROWTH 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 34 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
5.2.1 MARKET DRIVERS 69
5.2.1.1 Increasing incidence and prevalence of leukemia 69
FIGURE 35 INCIDENCE AND MORTALITY RATES OF LEUKEMIA, BY REGION, 2020 69
5.2.1.2 Increasing number of blood donations 69
TABLE 3 COLLECTION OF WHOLE BLOOD UNITS, BY COUNTRY,
2015–2016 (MILLION UNITS) 70
5.2.1.3 Demand for leukopaks in clinical research 70
FIGURE 36 GROWTH IN THE NUMBER OF CAR-T CLINICAL TRIALS 71
5.2.2 MARKET RESTRAINTS 71
5.2.2.1 High cost of therapeutic leukapheresis and leukopaks 71
TABLE 4 COST OF LEUKOPAKS, BY TYPE 72
5.2.2.2 Stringent donor recruitment criteria 72
TABLE 5 DONOR SELECTION CRITERIA 72
TABLE 6 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS 73
5.2.2.3 Dearth of skilled professionals and low adoption of therapeutic leukapheresis 73
5.2.2.4 Complications associated with therapeutic leukapheresis 74
5.2.2.5 Long procedural time for leukapheresis 74
5.2.2.6 High cost of cellular immunotherapies & lack of favorable reimbursement 74
5.2.3 MARKET OPPORTUNITIES 75
5.2.3.1 Leukapheresis for pediatric patients 75
5.2.3.2 Emerging economies and increasing investments from academic institutes, pharma-biotech companies, and leading players 75
5.2.4 MARKET CHALLENGES 75
5.2.4.1 Blood transfusion safety in developing countries 75
5.3 PORTER’S FIVE FORCES ANALYSIS 76
FIGURE 37 PORTER’S FIVE FORCES ANALYSIS (2020): LEUKAPHERESIS MARKET 76
TABLE 7 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 76
5.3.1 THREAT FROM NEW ENTRANTS 77
5.3.2 THREAT FROM SUBSTITUTES 77
5.3.3 BARGAINING POWER OF SUPPLIERS 77
5.3.4 BARGAINING POWER OF BUYERS 78
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.4 LEUKOPAKS: PRICING ANALYSIS 78
TABLE 8 ASP OF NON-MOBILIZED LEUKOPAKS 79
TABLE 9 ASP OF MOBILIZED LEUKOPAKS 79
TABLE 10 ASP OF MOBILIZED ISOLATED CELLS 80
5.5 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET) 81
5.5.1 NORTH AMERICA 81
5.5.1.1 US 81
5.5.1.2 Canada 81
5.5.2 EUROPE 81
5.5.3 ASIA PACIFIC 82
5.5.3.1 Japan 82
5.6 REGULATORY ANALYSIS (LEUKOPAKS MARKET) 82
5.6.1 US 83
TABLE 11 LIST OF FDA-APPROVED CAR-T THERAPEUTICS 83
5.6.2 EUROPE 83
5.6.3 JAPAN 83
5.6.4 CHINA 84
5.6.5 INDIA 85
5.7 VALUE CHAIN ANALYSIS 85
FIGURE 38 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS) 85
5.8 ECOSYSTEM MAP 86
TABLE 12 LEUKAPHERESIS MARKET: ECOSYSTEM 86
FIGURE 39 LEUKAPHERESIS MARKET: ECOSYSTEM MAP (2020) 87
5.9 PATENT ANALYSIS 87
5.9.1 PATENT PUBLICATION TRENDS IN THE LEUKAPHERESIS MARKET 87
FIGURE 40 GLOBAL PATENT PUBLICATION TRENDS IN THE LEUKAPHERESIS MARKET, 2015–2020 88
5.9.2 TOP APPLICANTS (COMPANIES) FOR LEUKAPHERESIS PATENTS 88
FIGURE 41 TOP APPLICANT COMPANIES FOR LEUKAPHERESIS PATENTS, 2015–2020 88
5.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR LEUKAPHERESIS MARKET PATENTS 89
FIGURE 42 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LEUKAPHERESIS PATENTS, 2015–2020 89
5.10 TECHNOLOGY ANALYSIS 89
5.10.1 KEY MARKETS FOR IMPORT AND EXPORT (TRADE ANALYSIS FOR APHERESIS-RELATED PRODUCTS & EQUIPMENT) 90
5.10.1.1 US 90
TABLE 13 US: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS 90
5.10.1.2 Russia 90
TABLE 14 RUSSIA: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS 90
5.10.1.3 China 91
TABLE 15 CHINA: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS 91
6 INDUSTRY INSIGHTS 92
6.1 INTRODUCTION 92
6.2 INDUSTRY TRENDS 92
6.2.1 INCREASING NUMBER OF COLLABORATIONS AMONG PHARMA AND BIOTECH COMPANIES 92
TABLE 16 RECENT PHARMA-BIOTECH COLLABORATIONS FOR CAR-T THERAPY 93
6.2.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS 94
6.2.3 USE OF LEUKAPHERESIS IN CLINICAL TRIALS TO DETERMINE CHANGES IN CELLULAR IMMUNE PROFILES IN COVID-19 INFECTIONS 94
7 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE 95
7.1 INTRODUCTION 96
TABLE 17 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 96
TABLE 18 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 96
7.2 LEUKAPHERESIS DISPOSABLES 97
7.2.1 RECURRENT USAGE AND DEMAND FOR DISPOSABLES BOOSTING
THE GROWTH OF THIS SEGMENT 97
TABLE 19 MANUFACTURERS OF LEUKOREDUCTION FILTERS 97
TABLE 20 MANUFACTURERS OF LEUKAPHERESIS COLUMNS & CELL SEPARATORS 98
TABLE 21 LEUKAPHERESIS DISPOSABLES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 98
7.3 LEUKAPHERESIS DEVICES 99
TABLE 22 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 99
TABLE 23 LEUKAPHERESIS DEVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 100
7.3.1 CENTRIFUGAL DEVICES 100
7.3.1.1 Increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis to drive market growth 100
TABLE 24 LIST OF CENTRIFUGAL APHERESIS DEVICES AVAILABLE IN THE MARKET 101
TABLE 25 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 101
7.3.2 MEMBRANE SEPARATORS 102
7.3.2.1 Difficulties in separating huge volumes of plasma from milliliters of whole blood—a key factor limiting the adoption of these devices 102
TABLE 26 LIST OF MEMBRANE SEPARATORS AVAILABLE IN THE MARKET 102
TABLE 27 MEMBRANE SEPARATORS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 103
8 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION 104
8.1 INTRODUCTION 105
TABLE 28 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 105

8.2 RESEARCH APPLICATIONS 105
8.2.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE THE GROWTH OF
THIS SEGMENT 105
TABLE 29 LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 106
8.3 THERAPEUTIC APPLICATIONS 106
8.3.1 INCREASING ADOPTION OF LEUKAPHERESIS PROCEDURES AS A SUPPORTIVE TREATMENT IN LEUKEMIA TO DRIVE MARKET GROWTH 106
TABLE 30 LEUKAPHERESIS PRODUCTS MARKET FOR THERAPEUTIC APPLICATIONS,
BY COUNTRY, 2019–2026 (USD THOUSAND) 107
9 LEUKAPHERESIS PRODUCTS MARKET, BY END USER 108
9.1 INTRODUCTION 109
TABLE 31 LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 109
9.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS 109
9.2.1 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS ARE THE LARGEST
END USERS OF LEUKAPHERESIS PRODUCTS 109
TABLE 32 LEUKAPHERESIS PRODUCTS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2019–2026 (USD MILLION) 110
9.3 ACADEMIC & RESEARCH INSTITUTES 110
9.3.1 COLLABORATIONS BETWEEN PHARMACEUTICAL COMPANIES AND ACADEMIC & RESEARCH INSTITUTES WILL DRIVE MARKET GROWTH 110
TABLE 33 LEUKAPHERESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 111
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 111
9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE THE GROWTH OF
THIS END-USER SEGMENT 111
TABLE 34 LEADING PHARMA-BIOTECH COMPANIES INVOLVED IN THE DEVELOPMENT OF CAR T-CELL TECHNOLOGIES 112
TABLE 35 LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 113
9.5 HOSPITALS & TRANSFUSION CENTERS 113
9.5.1 GROWTH IN THE NUMBER OF HOSPITALS PERFORMING TRANSFUSION TO DRIVE MARKET GROWTH 113
TABLE 36 LEUKAPHERESIS PRODUCTS MARKET FOR HOSPITALS & TRANSFUSION CENTERS, BY COUNTRY, 2019–2026 (USD MILLION) 114
10 LEUKOPAKS MARKET, BY TYPE 115
10.1 INTRODUCTION 116
TABLE 37 LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 116
TABLE 38 LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 117
10.2 MOBILIZED LEUKOPAKS 117
10.2.1 MOBILIZED LEUKOPAKS ACCOUNTED FOR THE LARGEST SHARE OF
THE MARKET 117
TABLE 39 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 40 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS) 118
10.3 NON-MOBILIZED LEUKOPAKS 119
10.3.1 LOW COST AS COMPARED TO MOBILIZED LEUKOPAKS TO DRIVE MARKET GROWTH 119
TABLE 41 COMPARATIVE ANALYSIS OF MOBILIZED LEUKOPAKS AND NON-MOBILIZED LEUKOPAKS 119
TABLE 42 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 120
TABLE 43 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS) 120
10.4 DISEASED LEUKOPAKS 120
10.4.1 RISING ADOPTION OF DISEASED LEUKOPAKS FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO DRIVE MARKET GROWTH 120
TABLE 44 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 121
TABLE 45 DISEASED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS) 121
10.5 ISOLATED PBMCS 122
10.5.1 INCREASING FOCUS OF RESEARCHERS ON CELL-BASED THERAPIES TO DRIVE MARKET GROWTH 122
TABLE 46 ISOLATED PBMCS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 123
TABLE 47 ISOLATED PBMCS MARKET, BY REGION, 2019–2026 (UNITS) 123
11 LEUKOPAKS MARKET, BY INDICATION 124
11.1 LEUKOPAKS MARKET, BY INDICATION 125
FIGURE 43 GLOBAL NUMBER OF CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR CELLS 125
TABLE 48 LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 126
TABLE 49 LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2019–2026 (USD MILLION) 126
TABLE 50 LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY REGION,
2019–2026 (USD MILLION) 127
TABLE 51 LEUKOPAKS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION,
2019–2026 (USD MILLION) 127
TABLE 52 LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2019–2026 (USD MILLION) 127
TABLE 53 LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY REGION,
2019–2026 (USD MILLION) 128
TABLE 54 LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY REGION, 2019–2026 (USD MILLION) 128
TABLE 55 LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY REGION,
2019–2026 (USD MILLION) 128
12 LEUKOPAKS MARKET, BY END USER 129
12.1 INTRODUCTION 130
TABLE 56 LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 130
12.2 ACADEMIC & RESEARCH INSTITUTES 130
12.2.1 INCREASING NUMBER OF INDUSTRY-ACADEMIC PARTNERSHIPS FOR CONDUCTING RESEARCH ON CELL-BASED CANCER THERAPIES TO DRIVE MARKET GROWTH 130
TABLE 57 LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2019–2026 (USD MILLION) 131
12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 131
12.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT UTILIZING LEUKOPAKS AS STARTING MATERIAL TO DRIVE MARKET GROWTH 131
TABLE 58 LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 132
12.4 CONTRACT RESEARCH ORGANIZATIONS 132
12.4.1 INCREASING SPONSORSHIP OF CLINICAL TRIALS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT 132
TABLE 59 LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 133
13 GEOGRAPHIC ANALYSIS 134
13.1 INTRODUCTION 135
FIGURE 44 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 135
TABLE 60 LEUKAPHERESIS PRODUCTS MARKET, BY REGION,
2019–2026 (USD MILLION) 136
FIGURE 45 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 136
TABLE 61 LEUKOPAKS MARKET, BY REGION, 2019–2026 (USD MILLION) 137
13.2 NORTH AMERICA 137
FIGURE 46 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 138
TABLE 62 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 138
TABLE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 64 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 65 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 139
TABLE 66 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION) 140
TABLE 67 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 140
TABLE 68 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE,
2019–2026 (USD MILLION) 140
TABLE 69 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION,
2019–2026 (USD MILLION) 141
TABLE 70 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER,
2019–2026 (USD MILLION) 141
13.2.1 US 141
13.2.1.1 The presence of a large number of leading pharmaceutical and biotechnology companies to drive market growth in the US 141
FIGURE 47 NUMBER OF REGISTERED CAR THERAPY CLINICAL TRIALS IN THE US,
2013–2020 142
TABLE 71 US: KEY MACROINDICATORS 142
TABLE 72 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 143
TABLE 73 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 143
TABLE 74 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 143
TABLE 75 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 143
TABLE 76 US: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 77 US: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 144
13.2.2 CANADA 144
13.2.2.1 Rising prevalence of blood cancer to stimulate market growth
in Canada 144
TABLE 78 CANADA: KEY MACROINDICATORS 145
TABLE 79 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 145
TABLE 80 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD THOUSAND) 145
TABLE 81 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD THOUSAND) 145
TABLE 82 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD THOUSAND) 146
TABLE 83 CANADA: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 146
TABLE 84 CANADA: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 146
13.3 EUROPE 147
FIGURE 48 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 147
TABLE 85 EUROPE: NUMBER OF REGISTERED CAR THERAPY CLINICAL TRIALS,
BY COUNTRY, 2015–2020 148
TABLE 86 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 148
TABLE 87 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 148
TABLE 88 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 149
TABLE 89 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 149
TABLE 90 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 149
TABLE 91 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 149
TABLE 92 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 150
TABLE 93 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 150
TABLE 94 EUROPE: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 150
13.3.1 UK 151
13.3.1.1 Rising prevalence of target diseases to drive market growth in the UK 151
TABLE 95 UK: KEY MACROINDICATORS 151
TABLE 96 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 97 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 152
TABLE 98 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD THOUSAND) 152
TABLE 99 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 152
TABLE 100 UK: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 153
TABLE 101 UK: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 153
13.3.2 GERMANY 153
13.3.2.1 Increasing research on cancer immunotherapies to drive market growth in Germany 153
TABLE 102 GERMANY: KEY MACROINDICATORS 153
TABLE 103 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 154
TABLE 104 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 154
TABLE 105 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD THOUSAND) 154
TABLE 106 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 154
TABLE 107 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 155
TABLE 108 GERMANY: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 155
13.3.3 SPAIN 155
13.3.3.1 Rising focus on the development of novel CAR T-cell therapies to drive market growth 155
TABLE 109 SPAIN: KEY MACROINDICATORS 156
TABLE 110 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 156
TABLE 111 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 156
TABLE 112 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD THOUSAND) 156
TABLE 113 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 157
TABLE 114 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 115 SPAIN: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 157
13.3.4 REST OF EUROPE 158
TABLE 116 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 158
TABLE 117 ROE: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 158
TABLE 118 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 159
TABLE 119 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 159
TABLE 120 ROE: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 159
TABLE 121 ROE: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 160
13.4 ASIA PACIFIC 160
FIGURE 49 APAC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 161
TABLE 122 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 161
TABLE 123 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 162
TABLE 124 APAC: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 162
TABLE 125 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 162
TABLE 126 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 162
TABLE 127 APAC: LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 163
TABLE 128 APAC: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 129 APAC: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 163
TABLE 130 APAC: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 164
13.4.1 CHINA 164
13.4.1.1 Market in China to witness the highest growth during the forecast period 164
FIGURE 50 NUMBER OF CAR T-BASED CLINICAL TRIALS REGISTERED IN CHINA
(2013–2020) 164
TABLE 131 CHINA: KEY MACROINDICATORS 165
TABLE 132 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 133 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 134 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 165
TABLE 135 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 166
TABLE 136 CHINA: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 166
TABLE 137 CHINA: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 166
13.4.2 JAPAN 167
13.4.2.1 Several research activities in Japan are focusing on the development of leukopak-based cell therapies 167
TABLE 138 JAPAN: KEY MACROINDICATORS 167
TABLE 139 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 140 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 168
TABLE 141 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD THOUSAND) 168
TABLE 142 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 168
TABLE 143 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 144 JAPAN: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 169
13.4.3 REST OF ASIA PACIFIC 169
TABLE 145 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 169
TABLE 146 ROAPAC: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 170
TABLE 147 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 170
TABLE 148 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 170
TABLE 149 ROAPAC: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 150 ROAPAC: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 171
13.5 REST OF THE WORLD 171
TABLE 151 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 172
TABLE 152 ROW: LEUKAPHERESIS DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 172
TABLE 153 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 172
TABLE 154 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY END USER,
2019–2026 (USD MILLION) 172
TABLE 155 ROW: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 156 ROW: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 173
TABLE 157 ROW: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION) 173
14 COMPETITIVE LANDSCAPE 174
14.1 INTRODUCTION 174
FIGURE 51 KEY DEVELOPMENTS OF MAJOR PLAYERS, JANUARY 2018–JANUARY 2021 175
FIGURE 52 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS DOMINATED THE LEUKAPHERESIS MARKET DURING 2018–2021 176
14.2 REVENUE SHARE ANALYSIS OF THE TOP 4 MARKET PLAYERS 177
FIGURE 53 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF THE TOP FOUR MARKET PLAYERS 177
14.3 PRODUCT FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE LEUKAPHERESIS AND LEUKOPAKS MARKETS 178
TABLE 158 COMPANY PRODUCT FOOTPRINT 178
TABLE 159 COMPANY INDUSTRY FOOTPRINT 179
TABLE 160 COMPANY APPLICATION FOOTPRINT 180
TABLE 161 COMPANY REGION FOOTPRINT 181
14.4 LEUKAPHERESIS MARKET SHARE (2020) 182
TABLE 162 LEUKAPHERESIS MARKET: DEGREE OF COMPETITION 182
FIGURE 54 LEUKAPHERESIS MARKET SHARE, BY KEY PLAYER (2020) 182
14.5 LEUKOPAKS MARKET SHARE (2020) 183
TABLE 163 LEUKOPAKS MARKET: DEGREE OF COMPETITION 183
FIGURE 55 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2020) 183
14.6 COMPETITIVE LEADERSHIP MAPPING (LEUKAPHERESIS MARKET) 184

14.7 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY 184
14.7.1 STARS 184
14.7.2 EMERGING LEADERS 184
14.7.3 PERVASIVE PLAYERS 185
14.7.4 PARTICIPANTS 185
FIGURE 56 LEUKAPHERESIS MARKET: COMPANY EVALUATION MATRIX, 2020 185
14.8 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (LEUKAPHERESIS MARKET) (2020) 186
14.8.1 PROGRESSIVE COMPANIES 186
14.8.2 DYNAMIC COMPANIES 186
14.8.3 STARTING BLOCKS 186
14.8.4 RESPONSIVE COMPANIES 186
FIGURE 57 LEUKAPHERESIS MARKET: SME/START-UP COMPANY EVALUATION MATRIX, 2020 187
14.9 COMPETITIVE LEADERSHIP MAPPING (LEUKOPAKS MARKET) 188
14.9.1 STARS 188
14.9.2 EMERGING LEADERS 188
14.9.3 PERVASIVE PLAYERS 188
14.9.4 PARTICIPANTS 188
FIGURE 58 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (2020) 189
14.10 COMPETITIVE SITUATIONS AND TRENDS 190
TABLE 164 PRODUCT LAUNCHES & APPROVALS (JANUARY 2018–JANUARY 2021) 190
TABLE 165 DEALS (JANUARY 2018–JANUARY 2021) 191
TABLE 166 OTHER DEVELOPMENTS (JANUARY 2018–JANUARY 2021) 193
15 COMPANY PROFILES 195
15.1 KEY PLAYERS (LEUKAPHERESIS MARKET) 195
(Business overview, Products offered, Recent developments, SWOT analysis, MNM view)*
15.1.1 ASAHI KASEI CORPORATION 195
TABLE 167 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW 195
FIGURE 59 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2020) 196
15.1.2 FRESENIUS SE & CO. KGAA 198
TABLE 168 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW 198
FIGURE 60 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2019) 199
FIGURE 61 FRESENIUS KABI: COMPANY SNAPSHOT (2019) 199
15.1.3 HAEMONETICS CORPORATION 202
TABLE 169 HAEMONETICS CORPORATION: BUSINESS OVERVIEW 202
FIGURE 62 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2018) 203
15.1.4 TERUMO BCT 206
TABLE 170 TERUMO BCT: BUSINESS OVERVIEW 206
FIGURE 63 TERUMO BCT: COMPANY SNAPSHOT (2020) 207
15.1.5 MACOPHARMA SA 210
TABLE 171 MACOPHARMA SA: BUSINESS OVERVIEW 210
15.1.6 MILTENYI BIOTEC 212
TABLE 172 MILTENYI BIOTEC: BUSINESS OVERVIEW 212
15.2 OTHER PLAYERS (LEUKAPHERESIS MARKET) 213
15.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD. 213
TABLE 173 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: BUSINESS OVERVIEW 213
15.2.2 MEDICA SPA. 214
TABLE 174 MEDICA SPA: BUSINESS OVERVIEW 214
15.2.3 PURIBLOOD MEDICAL CO. LTD. 215
TABLE 175 PURIBLOOD MEDICAL CO. LTD.: BUSINESS OVERVIEW 215
15.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD. 216
TABLE 176 BEIJING ZKSK TECHNOLOGY CO. LTD.: BUSINESS OVERVIEW 216
15.3 KEY PLAYERS (LEUKOPAKS MARKET) 217
15.3.1 ALLCELLS, LLC 217
TABLE 177 ALLCELLS, LLC: BUSINESS OVERVIEW 217
15.3.2 STEMEXPRESS, LLC 220
TABLE 178 STEMEXPRESS, LLC: BUSINESS OVERVIEW 220
15.3.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 223
TABLE 179 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 223
FIGURE 64 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2019) 224
FIGURE 65 HEMACARE CORPORATION: COMPANY SNAPSHOT (2018) 224
15.3.4 LONZA GROUP AG 227
TABLE 180 LONZA GROUP AG: BUSINESS OVERVIEW 227
FIGURE 66 LONZA GROUP AG: COMPANY SNAPSHOT (2019) 228
15.4 OTHER PLAYERS (LEUKOPAKS MARKET) 230
15.4.1 CALTAG MEDSYSTEMS LIMITED 230
TABLE 181 CALTAG MEDSYSTEMS LIMITED: BUSINESS OVERVIEW 230
15.4.2 ZENBIO, INC. 231
TABLE 182 ZENBIO, INC.: BUSINESS OVERVIEW 231
15.4.3 PRECISION FOR MEDICINE, INC. 232
TABLE 183 PRECISION FOR MEDICINE, INC.: BUSINESS OVERVIEW 232
15.4.4 BIOIVT 233
TABLE 184 BIOIVT: BUSINESS OVERVIEW 233
15.4.5 DISCOVERY LIFE SCIENCES 235
TABLE 185 DISCOVERY LIFE SCIENCES: BUSINESS OVERVIEW 235
15.4.6 INTELLIGENT TISSUE GROUP 236
*Business overview, Products offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.

16 APPENDIX 237
16.1 DISCUSSION GUIDE 237
16.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 244
16.3 AVAILABLE CUSTOMIZATIONS 246
16.4 RELATED REPORTS 246
16.5 AUTHOR DETAILS 247



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の白血球アフェレーシス療法市場(~2026年):製品別(デバイス、フィルター、カラム、使い​​捨て品)、ロイコパック別(可動性、非可動性)、疾患別(ALL、NHL、多発性骨髄腫)、用途別(研究、治療)、エンドユーザー別(病院、製薬、バイオテクノロジー)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆